Affymax Revenue Growth: -21.33%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AFFY Revenue Growth Rankings
| Overall | 7th percentile | 4103 of 4424 |
| Sector | 14th percentile | 399 of 464 in Healthcare |
| Industry | 24th percentile | 96 of 127 in Biotechnology |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AFFY related companies
AFFY News
$AFFY CEO will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14 @ 3:00 p.m EST.
about 3 days ago by abubnic
about 3 days ago by abubnic
@Trading4Cash I sold my PP at the close, same thing, made$$, I kind of regret selling my $affy one day early but go in early on that too!
about 8 days ago by professorkev
about 8 days ago by professorkev
@EXPstocktrader Are you on $AFFY too? Analyst have a $19 price target on it.
about 9 days ago by MaddStocks
about 9 days ago by MaddStocks
great run up in $AFFY this was the last squeeze as shorts took over for the time being. Locked in 10.45 reestablishing another entry
about 9 days ago by ACE52WeekHigh
about 9 days ago by ACE52WeekHigh
$AFFY Shares Given New $19.00 Price Target by Piper Jaffray Analysts. http://stks.co/2EAA
about 10 days ago by abubnic
about 10 days ago by abubnic
Affymax Promotes Cynthia Smith to Vice President, Market Access and Commercial Development
Feb 02, 4:00PM Business Wire
Feb 02, 4:00PM Business Wire
$AFFY beautiful. Approaching a beautiful rip towards $10. Vacuum buying in the mix!!!
about 10 days ago by ACE52WeekHigh
about 10 days ago by ACE52WeekHigh
Piper Jaffray Raises Target on Affymax (AFFY) to $19 Amid Optimistic Peginesatide Numbers
Feb 02, 11:40AM Street Insider
Feb 02, 11:40AM Street Insider
Baird Maintains an 'Outperform' on Affymax (AFFY); Even After Significant Model Revamp, It's Still A Buy
Dec 29, 7:07AM Street Insider
Dec 29, 7:07AM Street Insider
Takeda Pharmaceutical and Affymax (AFFX) Make Decision Not to Commercialize Peginesatide in Japan
Dec 15, 4:05PM Street Insider
Dec 15, 4:05PM Street Insider
Takeda and Affymax Provide Update on Peginesatide Commercialization Rights in Japan
Dec 15, 4:03PM Benzinga
Dec 15, 4:03PM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AFFY | 10.47 | -0.06 | -0.57% | 372.21M |
| LINTA | 18.16 | -0.07 | -0.36% | 10.40B |
| AVCA | 6.00 | 0.10 | 1.69% | 34.92M |
| CSCO | 19.89 | -0.10 | -0.53% | 106.74B |
| HBAN | 5.91 | -0.12 | -2.07% | 5.10B |
| DELL | 17.75 | -0.31 | -1.72% | 32.38B |
| NTAP | 39.69 | -1.43 | -3.47% | 14.62B |
| ATPG | 6.69 | -0.14 | -2.05% | 345.34M |
| CTIC | 1.08 | -0.02 | -1.82% | 208.31M |
| INTC | 26.70 | -0.17 | -0.61% | 135.93B |
